Oruka Therapeutics, Inc. Common Stock (ORKA) Stock Price
ORKAStock
$71.93+170.82%52W
Market Cap$4.76B
P/E—
PEG Ratio—
Div yield—
Beta-0.39
ORKA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-2.64%
Price vs S&P 500 (4W)-21.65%
VGM Score42.79
ORKA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.50 | -$0.55 | -9.95%(-$0.05) | |
| Q1 2026 | -$0.54 | -$0.48 | +10.61%(+$0.06) | |
| Q4 2025 | -$0.62 | -$0.45 | +26.89%(+$0.17) | |
| Q3 2025 | -$0.52 | -$0.55 | -4.96%(-$0.03) | |
| Q2 2025 | -$0.43 | -$0.46 | -6.36%(-$0.03) |
ORKA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.40
4.40
4.40
4.40
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. Common Stock | F | — | B | 101.6x | — | — | — | $71.93 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Oruka Therapeutics, Inc. Common Stock
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibodies for psoriasis and inflammatory diseases. Its lead programs—ORKA-001 and ORKA-002—target distinct inflammatory pathways (IL-23p19 and IL-17A/F) using high-affinity antibodies with extended half-lives to reduce dosing frequency. Both programs address psoriasis, with ORKA-002 also designed for psoriatic arthritis and related conditions.